Kawasaki‑like COVID‑19 Syndrome (Multisystem Inflammatory Syndrome in Children)

What is Kawasaki‑like COVID‑19 syndrome?

Kawasaki‑like COVID‑19 syndrome, more formally called Multisystem Inflammatory Syndrome in Children (MIS‑C) or Multisystem Inflammatory Syndrome in Adults (MIS‑A) when it occurs in adults, is a rare but serious condition that can develop several weeks after exposure to the SARS‑CoV‑2 virus. The illness shares many clinical features with classic Kawasaki disease—a vasculitis that primarily affects medium‑sized arteries in children—but is triggered by an abnormal immune response to COVID‑19 rather than a direct viral invasion of the blood vessels.

Children and adolescents typically present with persistent fever, widespread inflammation, and involvement of at least two organ systems (e.g., heart, gastrointestinal tract, skin, neurologic). The exact pathophysiology is still being investigated, but current evidence suggests a post‑infectious hyper‑immune reaction that leads to cytokine storm and endothelial damage.¹

Common Causes

While the syndrome itself is a reaction to COVID‑19, several underlying or co‑existing factors increase the risk of developing Kawasaki‑like features. The list below highlights the most recognized contributors:

• Recent SARS‑CoV‑2 infection (usually 2–6 weeks prior, confirmed by PCR or antibody testing).
• Genetic predisposition – certain HLA types and ethnic backgrounds (e.g., Asian, African‑American, Hispanic) appear more vulnerable.²
• Pre‑existing inflammatory conditions such as juvenile idiopathic arthritis or inflammatory bowel disease.
• Obesity – adipose tissue can amplify cytokine production.
• Underlying cardiac abnormalities (congenital heart disease) that may exacerbate myocardial inflammation.
• Autoimmune diseases (e.g., systemic lupus erythematosus) that prime the immune system.
• Severe or prolonged COVID‑19 illness – the higher the viral load, the greater the likelihood of a dysregulated immune response.
• Exposure to other viral infections (e.g., influenza, adenovirus) concurrently with SARS‑CoV‑2, which can synergistically trigger inflammation.
• Immunosuppressive therapy (e.g., chemotherapy) that alters normal immune regulation.
• Environmental triggers – high‑pollution areas have been associated with increased systemic inflammation in some studies.³

Associated Symptoms

Symptoms often develop gradually and may mimic other febrile illnesses. The CDC defines MIS‑C by the presence of fever lasting ≥24 hours plus at least two of the following categories:

• Cardiac: chest pain, palpitations, low blood pressure, myocarditis, pericardial effusion, coronary artery dilatation/aneurysm.
• Dermatologic/Mucocutaneous: diffuse rash, cracked “strawberry” tongue, erythematous oral mucosa, conjunctival injection (non‑purulent red eyes), swollen hands/feet.
• Gastrointestinal: abdominal pain, vomiting, diarrhea, liver enzyme elevation.
• Neurologic: headache, confusion, seizures, irritability.
• Hematologic: markedly elevated inflammatory markers (CRP, ESR, ferritin), neutrophilia, lymphopenia, thrombocytopenia or thrombocytosis.
• Respiratory: cough or shortness of breath may be present but are usually mild compared with acute COVID‑19.

Typical presentation in children includes:

• High fever (often > 39 °C) lasting > 3 days.
• Red eyes (conjunctivitis) without discharge.
• Bright red, cracked lips and a “strawberry” tongue.
• Swollen, painful palms and soles.
• Rash that may be maculopapular, erythema multiforme‑like, or diffuse.
• Abdominal pain that can mimic appendicitis.

When to See a Doctor

Early medical evaluation is crucial. Seek care promptly if a child or adolescent develops any of the following after a known or suspected COVID‑19 infection:

• Fever lasting more than 24 hours, especially if it spikes above 38.5 °C.
• Persistent abdominal pain, vomiting, or diarrhea that does not improve.
• Red, swollen eyes or a rash that spreads quickly.
• Rapid heart rate, low blood pressure, or feeling faint.
• Difficulty breathing, chest pain, or unexplained fatigue.
• Neurologic changes – confusion, severe headache, seizures.

If any of these signs appear, contact your pediatrician or go to the nearest emergency department. Early intervention reduces the risk of cardiac complications.

Diagnosis

The diagnosis of Kawasaki‑like COVID‑19 syndrome is clinical, supported by laboratory and imaging studies. Typical steps include:

1. History & Physical Exam – Confirm recent COVID‑19 exposure (positive PCR or serology) and document fever duration, rash, mucosal changes, and organ‑system involvement.
2. Laboratory Tests
   • Complete blood count (CBC) – often shows neutrophilia, lymphopenia, and either low or high platelet counts.
   • Inflammatory markers – C‑reactive protein (CRP) > 3 mg/dL, erythrocyte sedimentation rate (ESR) > 40 mm/hr, ferritin, procalcitonin.
   • Cardiac enzymes – troponin and B‑type natriuretic peptide (BNP) elevation suggest myocardial injury.
   • Comprehensive metabolic panel – assesses liver and kidney function.
   • SARS‑CoV‑2 testing – PCR (if still positive) and/or antibody serology.
3. Cardiac Evaluation
   • Electrocardiogram (ECG) – may reveal arrhythmias or ST changes.
   • Echocardiogram – essential to assess ventricular function, pericardial effusion, and coronary artery dimensions; aneurysms are seen in 10‑20 % of cases.⁴
4. Imaging of Other Systems
   • Abdominal ultrasound or CT if severe abdominal pain is present – helps rule out surgical abdomen.
   • Chest X‑ray – evaluates for pulmonary infiltrates, though usually mild.
5. Exclusion of Other Diseases – Blood cultures, viral panels, and autoimmune work‑up are performed to rule out sepsis, toxic shock syndrome, or other vasculitides.

Treatment Options

Management focuses on controlling inflammation, supporting organ function, and preventing long‑term cardiac damage. Treatment is usually initiated in a hospital setting, often in a pediatric intensive care unit (PICU) for severe cases.

First‑line Therapy

• Intravenous Immunoglobulin (IVIG) – 2 g/kg given over 8‑12 hours. Evidence shows IVIG reduces fever duration and coronary artery complications, mirroring Kawasaki disease treatment.⁵
• Aspirin – High‑dose (80‑100 mg/kg/day) during the acute phase, then low‑dose (3‑5 mg/kg/day) after fever resolves, to inhibit platelet aggregation.

Adjunctive Immunomodulators

• Corticosteroids – Methylprednisolone 1‑2 mg/kg/day (or pulse dosing) is added for patients with refractory fever, shock, or significant cardiac involvement.
• Biologic agents (used when IVIG ± steroids fail):
  • **Anakinra** (IL‑1 receptor antagonist) – 2‑10 mg/kg/day.
  • **Tocilizumab** (IL‑6 inhibitor) – 8 mg/kg IV.
  • **Infliximab** (TNF‑α blocker) – 5‑10 mg/kg IV.

Supportive Care

• Fluid resuscitation and vasopressors (e.g., norepinephrine) for shock.
• Oxygen therapy or mechanical ventilation if respiratory failure develops.
• Anticoagulation (low‑molecular‑weight heparin) for patients with markedly elevated D‑dimer or documented thrombus.
• Monitoring and treatment of arrhythmias or myocardial dysfunction.

Home & Follow‑up Care

After discharge, most children continue low‑dose aspirin for 4–6 weeks and have repeat echocardiograms at 1‑2 weeks, 6‑8 weeks, and 6 months to track coronary artery status. Families should monitor for recurrent fever, new rashes, or worsening fatigue and report these immediately.

Prevention Tips

Because the syndrome is a post‑infection complication, primary prevention of SARS‑CoV‑2 infection is the most effective strategy.

• Vaccination – Up‑to‑date COVID‑19 vaccination (including booster doses) dramatically lowers the risk of severe infection and MIS‑C.⁶
• Mask‑wearing in crowded indoor settings, especially during community surges.
• Hand hygiene – Regular washing with soap for at least 20 seconds or using an alcohol‑based sanitizer.
• Ventilation – Keep windows open or use HEPA filters in homes and schools.
• Prompt testing and isolation if a child develops COVID‑19 symptoms or has known exposure.
• Maintain a healthy lifestyle – Balanced diet, adequate sleep, and regular physical activity support a resilient immune system.
• Follow public‑health guidance during outbreaks (e.g., stay‑at‑home orders, quarantine recommendations).

Emergency Warning Signs

Key Take‑aways

Kawasaki‑like COVID‑19 syndrome (MIS‑C/MIS‑A) is a rare, immune‑mediated complication that can develop weeks after a SARS‑CoV‑2 infection. Early recognition, timely hospital care, and aggressive anti‑inflammatory treatment dramatically improve outcomes and reduce the risk of lasting heart damage. Vaccination and standard infection‑control measures remain the cornerstone of prevention.

References

1. Mayo Clinic. “Multisystem inflammatory syndrome in children (MIS‑C).” 2023. Link.
2. World Health Organization. “Multisystem inflammatory syndrome in children and adolescents temporally related to COVID‑19.” WHO Brief, 2022.
3. Centers for Disease Control and Prevention. “MIS‑C Clinical Guidance.” Updated 2024. Link.
4. Cleveland Clinic. “Coronary artery aneurysms in MIS‑C.” 2022. Link.
5. Feldstein LR, et al. “Multisystem Inflammatory Syndrome in US Children and Adolescents.” New England Journal of Medicine. 2020;383:334‑346. doi:10.1056/NEJMoa2021680.
6. CDC. “COVID‑19 Vaccine Effectiveness in Preventing MIS‑C.” 2023. Link.